Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Overview

Información sobre este estudio

The purpose of this study is to determine the impact of HBOT (hyperbaric oxygen therapy) on clinical response/remission to medical therapy as measured bycomplete resolution of rectal bleeding (Mayo rectal bleeding sub-score of 0) and improvement in stool frequency (at least 1 point reduction in Mayo stool frequency sub-score), without the need for biologics, small molecules, or colectomy, by study day 5.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Participants with known or newly diagnosed UC who require hospitalization for an acute moderate to severe flare.

- Age 18-85.

- Consented and able to receive first HBOT session within first 48 hours of initiation of intravenous steroids.

Exclusion Criteria:

- Complication requiring urgent surgical intervention.

- Toxic megacolon.

- Inability to receive intravenous steroids.

- Historically failed 3 or more classes of advanced therapeutic options.

- Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic
colitis or infectious colitis.

- Received any investigational drug within 30 days.

- Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment that increases the risk for HBOT toxicity.

- Women who are pregnant or nursing.

- Unwillingness to complete course of HBOT.

- Active SARS CoV 2 infection.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/14/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Laura Raffals, M.D.

Abierto para la inscripción

Contact information:

Chad Rypstra

(507) 538-4289

Rypstra.Chad@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20559899

Mayo Clinic Footer